Lyme PrEP Antibody Treatment Description
Lyme PrEP uses a single human antibody, or blood protein, to kill the bacteria in the tick’s gut while the tick drinks its victim’s blood before the bacteria can get into the human host.
A panel of anti-OspA human mAbs (HuMAbs) as potential prophylaxis for Lyme disease was developed. In particular, HuMAb 2217 was shown to be borreliacidal (EC50 < 1 nM) against B. burgdorferi, B. afzelii, and B. garinii, the 3 main genospecies endemic in the United States, Europe, and Asia. When passively administered to mice prior to challenge with B. burgdorferi–infected Ixodes ticks, HuMAb 2217 completely prevented transmission after a single dose of 10 mg/kg.
One challenge to developing 2217 for Lyme disease prevention is to ensure that the antibody sustains a protective plasma concentration for the entire tick season.
HuMab 2217 was modified (HuMab 2217LS), to successfully double its half-life, which could provide sufficient protection during the Lyme disease season.
Lyme PrEP Antibody Treatment Indication
Lyme PrEP would be indicated for those populations living in areas where black-legged or deer ticks are found.
Lyme disease in humans is characterized by erythema migrans (EM); fever; fatigue; musculoskeletal pain; and the potential for neurological, cardiac, or joint manifestations. The CDC has estimated that over 476,000 Americans are diagnosed with and treated for Lyme disease each year.
Lyme PrEP Antibody Treatment Dosage
Phase 1 trial indicates that a single shot will give protection for the necessary amount of time, but will be confirmed during the later phases of the clinical trials.
Lyme PrEP Antibody Treatment Side Effects
Unlike a vaccine, which induces many antibodies that may not contribute to protection but can cause side effects, the Lyme PrEP approach uses a single, defined antibody, thus reducing the risk of side effects.
Lyme PrEP Antibody Treatment Clinical Trial
LymePrEP is currently recruiting for a Phase 1 clinical trial. The title of the trial is First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People.